{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:18:01Z","timestamp":1787822281043,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973555"],"award-info":[{"award-number":["81973555"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202101ZYTS106"],"award-info":[{"award-number":["YDZJ202101ZYTS106"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nat Med"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11418-024-01780-8","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T10:02:12Z","timestamp":1707472932000},"page":"427-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Angelica dahurica extract and its effective component bergapten alleviated hepatic fibrosis by activating FXR signaling pathway"],"prefix":"10.1007","volume":"78","author":[{"given":"Chong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-He","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6221-4309","authenticated-orcid":false,"given":"Ji-Xing","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"1780_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18:151\u2013166","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.2147\/DDDT.S186726","volume":"12","author":"M Mu","year":"2018","unstructured":"Mu M, Zuo S, Wu RM, Deng KS, Lu S, Zhu JJ, Zou G, Yang J, Cheng ML, Zhao XK (2018) Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-\u03b2\/Smad signaling pathway. Drug Des Devel Ther 12:4107\u20134115","journal-title":"Drug Des Devel Ther"},{"key":"1780_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11418-020-01394-w","volume":"74","author":"X He","year":"2020","unstructured":"He X, Chen J, Mu Y, Zhang H, Chen G, Liu P, Liu W (2020) The effects of inhibiting the activation of hepatic stellate cells by lignan components from the fruits of Schisandra chinensis and the mechanism of schisanhenol. J Nat Med 74:513\u2013524","journal-title":"J Nat Med"},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40139-013-0018-7","volume":"1","author":"X Liu","year":"2013","unstructured":"Liu X, Xu J, Brenner DA, Kisseleva T (2013) Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep 1:209\u2013214","journal-title":"Curr Pathobiol Rep"},{"key":"1780_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jhbp.245","volume":"22","author":"E Seki","year":"2015","unstructured":"Seki E, Brenner DA (2015) Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci 22:512\u2013518","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola M, Pinzani M (2019) Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 65:37\u201355","journal-title":"Mol Aspects Med"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11418-017-1122-5","volume":"72","author":"D Yang","year":"2018","unstructured":"Yang D, Li L, Qian S, Liu L (2018) Evodiamine ameliorates liver fibrosis in rats via TGF-\u03b21\/Smad signaling pathway. J Nat Med 72:145\u2013154","journal-title":"J Nat Med"},{"key":"1780_CR8","doi-asserted-by":"publisher","first-page":"896473","DOI":"10.3389\/fimmu.2022.896473","volume":"13","author":"C Gan","year":"2022","unstructured":"Gan C, Cai Q, Tang C, Gao J (2022) Inflammasomes and pyroptosis of liver cells in liver fibrosis. Front Immunol 13:896473","journal-title":"Front Immunol"},{"key":"1780_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells8111419","volume":"8","author":"B Dewidar","year":"2019","unstructured":"Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN (2019) TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis-updated. Cells 8:1419","journal-title":"Cells"},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","volume":"347","author":"S Dooley","year":"2019","unstructured":"Dooley S, ten Dijke P (2019) TGF-\u03b2 in progression of liver disease. Cell Tissue Res 347:245\u2013256","journal-title":"Cell Tissue Res"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00109-017-1605-6","volume":"96","author":"A Xu","year":"2018","unstructured":"Xu A, Li Y, Zhao W, Hou F, Li X, Sun L, Chen W, Yang A, Wu S, Zhang B, Yao J, Wang H, Huang J (2018) PHP14 regulates hepatic stellate cells migration in liver fibrosis via mediating TGF-\u03b21 signaling to PI3K\u03b3\/AKT\/Rac1 pathway. J Mol Med (Berl) 96:119\u2013133","journal-title":"J Mol Med (Berl)"},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","volume":"499","author":"S Yoshimoto","year":"2018","unstructured":"Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N (2018) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97\u2013101","journal-title":"Nature"},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.jbc.2022.102530","volume":"298","author":"XX Wang","year":"2022","unstructured":"Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K, Bhasin K, Jones BA, Orlicky DJ, Takahashi S, Dvornikov A, Kleiner DE, Hewitt SM, Adorini L, Kopp JB, Krausz KW, Rosenberg A, McManaman JL, Robertson CE, Ir D, Frank DN, Luo Y, Gonzalez FJ, Gratton E, Levi M (2022) The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem 298:102530","journal-title":"J Biol Chem"},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1172\/JCI18945","volume":"112","author":"Y Liu","year":"2003","unstructured":"Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678\u20131687","journal-title":"J Clin Invest"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","volume":"43","author":"SY Tian","year":"2022","unstructured":"Tian SY, Chen SM, Pan CX, Li Y (2022) FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacol Sin 43:1120\u20131132","journal-title":"Acta Pharmacol Sin"},{"key":"1780_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1159\/000445268","volume":"34","author":"E Halilbasic","year":"2022","unstructured":"Halilbasic E, Fuchs C, Traussnigg S, Trauner M (2022) Farnesoid X receptor agonists and other bile acid signaling strategies for treatment of liver disease. Dig Dis 34:580\u2013588","journal-title":"Dig Dis"},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"108794","DOI":"10.1016\/j.cbi.2019.108794","volume":"311","author":"X Han","year":"2019","unstructured":"Han X, Cui ZY, Song J, Piao HQ, Lian LH, Hou LS, Wang G, Zheng S, Dong XX, Nan JX, Wu YL (2019) Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR\/LXRs-dependent manner. Chem Biol Interact 311:108794","journal-title":"Chem Biol Interact"},{"key":"1780_CR19","doi-asserted-by":"publisher","first-page":"896637","DOI":"10.3389\/fphar.2022.896637","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao H, Feng YL, Wang M, Wang JJ, Liu T, Yu J (2022) The Angelica dahurica: a review of traditional uses. Phytochemistry and Pharmacology Front Pharmacol 13:896637","journal-title":"Phytochemistry and Pharmacology Front Pharmacol"},{"key":"1780_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s10068-018-0359-4","volume":"27","author":"WH Liang","year":"2018","unstructured":"Liang WH, Chang TW, Charng YC (2018) Effects of drying methods on contents of bioactive compounds and antioxidant activities of Angelica dahurica. Food Sci Biotechnol 27:1085\u20131092","journal-title":"Food Sci Biotechnol"},{"key":"1780_CR21","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1002\/ptr.7221","volume":"35","author":"Y Liang","year":"2021","unstructured":"Liang Y, Xie L, Liu K, Cao Y, Dai X, Wang X, Lu J, Zhang X, Li X (2021) Bergapten: a review of its pharmacology, pharmacokinetics, and toxicity. Phytother Res 35:6131\u20136147","journal-title":"Phytother Res"},{"key":"1780_CR22","doi-asserted-by":"publisher","first-page":"8615242","DOI":"10.1155\/2022\/8615242","volume":"2022","author":"MM Quetglas-Llabr\u00e9s","year":"2022","unstructured":"Quetglas-Llabr\u00e9s MM, Quispe C, Herrera-Bravo J, Catarino MD, Pereira OR, Cardoso SM, Dua K, Chellappan DK, Pabreja K, Satija S, Mehta M, Sureda A, Martorell M, Satmbekova D, Yeskaliyeva B, Sharifi-Rad J, Rasool N, Butnariu M, Bagiu IC, Bagiu RV, Calina D, Cho WC (2022) Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxid Med Cell Longev 2022:8615242","journal-title":"Oxid Med Cell Longev"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3748\/wjg.v18.i18.2197","volume":"18","author":"WX Liu","year":"2012","unstructured":"Liu WX, Jia FL, He YY, Zhang BX (2012) Protective effects of 5-methoxypsoralen against acetaminophen-induced hepatotoxicity in mice. World J Gastroenterol 18:2197\u20132202","journal-title":"World J Gastroenterol"},{"key":"1780_CR24","first-page":"618","volume":"43","author":"P Wan","year":"2023","unstructured":"Wan P, Hengfan NI, Dale G, Yun D, Manyun D (2023) Farnesoid X receptor regulators from natural products and their biological function. J Tradit Chin Med 43:618\u2013626","journal-title":"J Tradit Chin Med"},{"issue":"10","key":"1780_CR25","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/cells10102759","volume":"10","author":"A Caligiuri","year":"2021","unstructured":"Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F (2021) Cellular and molecular mechanisms underlying liver fibrosis regression. Cells 10(10):2759","journal-title":"Cells"},{"key":"1780_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2131\/jts.41.561","volume":"41","author":"S Dong","year":"2016","unstructured":"Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, Hu YY, Liu P, Su SB (2016) Mechanisms of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. J Toxicol Sci 41:561\u2013572","journal-title":"J Toxicol Sci"},{"key":"1780_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.biopha.2012.10.002","volume":"67","author":"D Kong","year":"2013","unstructured":"Kong D, Zhang F, Zhang Z, Lu Y, Zheng S (2013) Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential. Biomed Pharmacother 67:246\u2013250","journal-title":"Biomed Pharmacother"},{"key":"1780_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0039-1685515","volume":"39","author":"A Wree","year":"2019","unstructured":"Wree A, Holtmann TM, Inzaugarat ME, Feldstein AE (2019) Novel drivers of the inflammatory response in liver injury and fibrosis. Semin Liver Dis 39:275\u2013282","journal-title":"Semin Liver Dis"},{"key":"1780_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11418-019-01334-3","volume":"74","author":"J Gong","year":"2020","unstructured":"Gong J, Yang F, Yang Q, Tang X, Shu F, Xu L, Wang Z, Yang L (2020) Sweroside ameliorated carbon tetrachloride (CCl4)-induced liver fibrosis through FXR-miR-29a signaling pathway. J Nat Med 74:17\u201325","journal-title":"J Nat Med"},{"key":"1780_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12664-021-01220-5","volume":"41","author":"T Namisaki","year":"2022","unstructured":"Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H (2022) Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Indian J Gastroenterol 41:169\u2013180","journal-title":"Indian J Gastroenterol"},{"key":"1780_CR31","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1021\/acs.jafc.0c01978","volume":"68","author":"J Song","year":"2020","unstructured":"Song J, Cui ZY, Lian LH, Han X, Hou LS, Wang G, Gao L, Zhu Y, Jiang YC, Dou JY, Hu ZH, Zhao YQ, Nan JX, Wu YL (2020) 20S-Protopanaxatriol ameliorates hepatic fibrosis, potentially involving FXR-mediated inflammatory signaling cascades. J Agric Food 68:8195\u20138204","journal-title":"J Agric Food"},{"key":"1780_CR32","doi-asserted-by":"publisher","first-page":"33453","DOI":"10.1038\/srep33453","volume":"6","author":"L Verbeke","year":"2016","unstructured":"Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W (2016) FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 6:33453","journal-title":"Sci Rep"}],"container-title":["Journal of Natural Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11418-024-01780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11418-024-01780-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11418-024-01780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:29:19Z","timestamp":1709134159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11418-024-01780-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1007\/s11418-024-01780-8","relation":{},"ISSN":["1340-3443","1861-0293"],"issn-type":[{"value":"1340-3443","type":"print"},{"value":"1861-0293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}